1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

 
• By Emily Hayes

Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.

Leukemia cell (blast cell)

The acute myeloid leukemia field looks set for a shakeup with the potential US market entry of Novartis AG's midostaurin, several other candidates in Phase III, and a new master trial aimed at rapid development of targeted drugs.

Progress in AML has been slow – the five-year survival rate is only 26% – and the standard of care has been the same for decades

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.